SCHEMBL7079274

SCHEMBL7079274

O=c1[nH]c2c(cnn2-c2ccccc2)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.49
ALDH1A1 P00352 6/20 0.49
NPC1 O15118 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 3/20 0.49
MAPT P10636 3/20 0.49
PAX8 Q06710 2/20 0.49
RXFP1 Q9HBX9 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MEN1 O00255 1/20 0.41
GLA P06280 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
KMT2A Q03164 1/20 0.41
RELA Q04206 1/20 0.41
HPGD P15428 2/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7078016 0.80 KMT2A (0.45) RAB9AALDH1A1LMNAHTTMAPT
SCHEMBL1884775 0.79 MAPK14 (0.41) MAPK14
SCHEMBL28936095 0.76 HSD17B10 (0.51) ALDH1A1HTTMAPTMEN1KMT2A
SCHEMBL2643791 0.75 HCAR1 (0.48) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL3770447 0.75 TP53 (0.40) GLATP53L3MBTL1THRBMAPK14
SCHEMBL2644551 0.71 RAB9A (0.49) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL31598871 0.69 PLAT (0.37) MAPK1
SCHEMBL6035072 0.68 RAB9A (0.49) RAB9AALDH1A1LMNAHTTMAPT
SCHEMBL4743412 0.66 RAB9A (1.00) RAB9AALDH1A1NPC1SMN1; SMN2LMNA
SCHEMBL31598862 0.66 GRM2 (0.36) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541484-B2 Central nervous system disorders; psychological disorders MERCK SHARP & DOHME LIMITED 2003-04-01 US disclosed
US-20030004180-A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004180-A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors GABRA3, GABRA4, GABRB3 RAB9A 2107/4885ALDH1A1 1355/4885NPC1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.